Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis

Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis

Abstract Background Activation of melanocortin 1 receptor (MC1R) is known to exert broad anti-inflammatory and anti-fibrotic effects. The purpose of this study is to investigate the potential of dersimelagon, a novel oral MC1R agonist, as a therapeutic agent for systemic sclerosis (SSc). Methods The...

Full description

Bibliographic Details
Main Authors: Masahiro Kondo, Tsuyoshi Suzuki, Yuko Kawano, Shinji Kojima, Masahiko Miyashiro, Atsuhiro Matsumoto, Gabriela Kania, Przemysław Błyszczuk, Rebecca L. Ross, Panji Mulipa, Francesco Del Galdo, Yun Zhang, Jörg H. W. Distler
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Arthritis Research & Therapy
Subjects:
Systemic sclerosis
Melanocortin 1 receptor
Fibroblast
Inflammation
Vascular dysfunction
Fibrosis
Online Access:https://doi.org/10.1186/s13075-022-02899-3

Internet

https://doi.org/10.1186/s13075-022-02899-3

Similar Items